The business is growing strongly, led by acoramidis and a late-stage pipeline with three major launches by 2027. ATTR-CM stabilizers are frontline, with Attruby set for greater market share. Launches in limb-girdle muscular dystrophy, ADH1, and achondroplasia are backed by focused strategies and favorable payer dynamics.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr
